<p>LENZ Therapeutics, Inc.（纳斯达克代码：LENZ - 获取免费报告）董事 James Mccollum 于 11 月 7 日星期五以每股平均 22.79 美元的价格购买了 10,500 股公司股票，总交易额为 239,295.00 美元。收购完成后，该董事直接持有 10,500 股公司股票，估值约为 239,295 美元。此次交易使其持股量增加了∞。该购买在向 SEC 提交的文件中披露，文件可通过此链接获取。</p>
<p>获取 <strong>LENZ Therapeutics</strong> 的提醒：</p>
<h2>LENZ Therapeutics 股票表现</h2>
<p>纳斯达克 LENZ 周一上涨 0.22 美元，达到 23.19 美元。该公司股票成交量为 1,048,967 股，较其平均成交量 452,223 股有所增加。LENZ Therapeutics, Inc.的 52 周最低价为 16.53 美元，52 周最高价为 50.40 美元。该公司的市值为 7.2562 亿美元，市盈率为-10.99，贝塔值为 0.46。该股票的 50 日移动平均价格为 38.39 美元，200 日移动平均价格为 33.94 美元。</p>
<p>LENZ Therapeutics（纳斯达克代码：LENZ - 获取免费报告）于 11 月 5 日星期三发布了季度财报。公司报告本季度每股收益为（0.59 美元），超出分析师一致预期的（0.67 美元）0.08 美元。公司本季度收入为 1250 万美元，而分析师预期为 464 万美元。整体来看，股票研究分析师预计 LENZ Therapeutics, Inc.在当前财政年度将发布-2.18 的每股收益。</p>
<h2>华尔街分析师预测增长</h2>
<p>多家研究分析师对 LENZ 股票发布了报告。HC Wainwright 在 10 月 27 日的报告中重申了 “买入” 评级，并对 LENZ Therapeutics 的股票设定了 56.00 美元的目标价。Zacks Research 在 10 月 22 日的研究报告中将 LENZ Therapeutics 的股票评级从 “持有” 上调至 “强力买入”。Weiss Ratings 在 10 月 8 日的报告中重申了 LENZ Therapeutics 的 “卖出（d-）” 评级。Raymond James Financial 在 10 月 20 日的报告中重申了 “跑赢大盘” 评级，并将 LENZ Therapeutics 的目标价上调至 50.00 美元（之前为 40.00 美元）。最后，花旗集团在 7 月 31 日的研究报告中重申了 “买入” 评级，并将 LENZ Therapeutics 的目标价上调至 49.00 美元（之前为 45.00 美元）。一位分析师给予该股票 “强力买入” 评级，五位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，LENZ Therapeutics 目前的平均评级为 “适度买入”，平均目标价为 56.40 美元。</p>
<p><strong>查看我们对 LENZ Therapeutics 的最新分析</strong></p>
<h2>对 LENZ Therapeutics 的对冲基金看法</h2>
<p>对冲基金和其他机构投资者最近增加或减少了对该股票的持仓。Versant Venture Management LLC 在第三季度收购了价值约 123,758,000 美元的 LENZ Therapeutics 新股份。Paradigm Biocapital Advisors LP 在第一季度将其在 LENZ Therapeutics 的持股增加了 96.2%。Paradigm Biocapital Advisors LP 目前拥有 1,511,932 股公司股票，价值 3,887,200 美元，此前在上个季度又购买了 741,477 股。Adage Capital Partners GP L.L.C.在第二季度将其在 LENZ Therapeutics 的持股增加了 108.8%。Adage Capital Partners GP L.L.C.目前拥有 1,122,738 股公司股票，价值 32,907,000 美元，此前在上个季度又购买了 585,000 股。Saturn V Capital Management LP 在第二季度购买了价值约 10,033,000 美元的 LENZ Therapeutics 新股份。最后，Invesco Ltd.在第二季度收购了价值约 7,816,000 美元的 LENZ Therapeutics 新股份。54.32% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 LENZ Therapeutics</h2>
<p>（获取免费报告）</p>
<p>LENZ Therapeutics, Inc.是一家生物制药公司，专注于开发和商业化改善美国视力的疗法。其产品候选包括 LNZ100 和 LNZ101，目前正在进行治疗老花眼的第三阶段临床试验。该公司总部位于加利福尼亚州德尔玛。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票比 LENZ Therapeutics 更好</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>股票下跌，目标价上升：3 只在上涨超过 10% 后被升级的股票</li>
<li>什么是欧元区 STOXX 50 指数？</li>
<li>核能股票正在崩溃——投资者应该恐慌吗？</li>
<li>经济报告在成功投资策略中的作用</li>
<li>Monday.com 因疯狂抛售而开启了世代机会</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 LENZ Therapeutics 吗？</h2>
<p>在你考虑 LENZ Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 LENZ Therapeutics 并不在名单上。</p>
<p>虽然 LENZ Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

LENZ

<p>LENZ Therapeutics（纳斯达克代码：LENZ）董事 James Mccollum 以平均价格 22.79 美元购入 10,500 股，总计 239,295 美元。这笔交易增加了他在公司的持股，现持股总值约为 239,295 美元。该交易已向美国证券交易委员会（SEC）披露。收购后，LENZ 股票交易价格为 23.19 美元，市值为 7.2562 亿美元。分析师对 LENZ 的评级不一，平均目标价共识为 56.40 美元。该公司专注于开发改善视力的疗法，总部位于加利福尼亚州德尔玛</p>

<p>LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) Director James Mccollum acquired 10,500 shares of the company's stock in a transaction dated Friday, November 7th. The stock was acquired at an average cost of $22.79 per share, for a total transaction of $239,295.00. Following the completion of the acquisition, the director directly owned 10,500 shares in the company, valued at approximately $239,295. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.</p>
<div class="lb-trans"><p>LENZ Therapeutics, Inc.（纳斯达克代码：LENZ - 获取免费报告）董事 James Mccollum 于 11 月 7 日星期五以每股平均 22.79 美元的价格购买了 10,500 股公司股票，总交易额为 239,295.00 美元。收购完成后，该董事直接持有 10,500 股公司股票，估值约为 239,295 美元。此次交易使其持股量增加了∞。该购买在向 SEC 提交的文件中披露，文件可通过此链接获取。</p>
</div><p>Get <strong>LENZ Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>LENZ Therapeutics</strong> 的提醒：</p>
</div><h2>LENZ Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>LENZ Therapeutics 股票表现</h2>
</div><p>NASDAQ LENZ traded up $0.22 on Monday, reaching $23.19. 1,048,967 shares of the company's stock traded hands, compared to its average volume of 452,223. LENZ Therapeutics, Inc. has a fifty-two week low of $16.53 and a fifty-two week high of $50.40. The firm has a market cap of $725.62 million, a price-to-earnings ratio of -10.99 and a beta of 0.46. The stock has a 50 day moving average price of $38.39 and a 200-day moving average price of $33.94.</p>
<div class="lb-trans"><p>纳斯达克 LENZ 周一上涨 0.22 美元，达到 23.19 美元。该公司股票成交量为 1,048,967 股，较其平均成交量 452,223 股有所增加。LENZ Therapeutics, Inc.的 52 周最低价为 16.53 美元，52 周最高价为 50.40 美元。该公司的市值为 7.2562 亿美元，市盈率为-10.99，贝塔值为 0.46。该股票的 50 日移动平均价格为 38.39 美元，200 日移动平均价格为 33.94 美元。</p>
</div><p>LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.59) earnings per share for the quarter, beating analysts' consensus estimates of ($0.67) by $0.08. The company had revenue of $12.50 million for the quarter, compared to analysts' expectations of $4.64 million. As a group, equities research analysts anticipate that LENZ Therapeutics, Inc. will post -2.18 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>LENZ Therapeutics（纳斯达克代码：LENZ - 获取免费报告）于 11 月 5 日星期三发布了季度财报。公司报告本季度每股收益为（0.59 美元），超出分析师一致预期的（0.67 美元）0.08 美元。公司本季度收入为 1250 万美元，而分析师预期为 464 万美元。整体来看，股票研究分析师预计 LENZ Therapeutics, Inc.在当前财政年度将发布-2.18 的每股收益。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of research analysts have issued reports on LENZ shares. HC Wainwright reissued a &#34;buy&#34; rating and issued a $56.00 price target on shares of LENZ Therapeutics in a report on Monday, October 27th. Zacks Research upgraded shares of LENZ Therapeutics from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Wednesday, October 22nd. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of LENZ Therapeutics in a report on Wednesday, October 8th. Raymond James Financial reaffirmed an &#34;outperform&#34; rating and issued a $50.00 price objective (up previously from $40.00) on shares of LENZ Therapeutics in a report on Monday, October 20th. Finally, Citigroup reiterated a &#34;buy&#34; rating and issued a $49.00 price objective (up previously from $45.00) on shares of LENZ Therapeutics in a research report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, LENZ Therapeutics presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $56.40.</p>
<div class="lb-trans"><p>多家研究分析师对 LENZ 股票发布了报告。HC Wainwright 在 10 月 27 日的报告中重申了 “买入” 评级，并对 LENZ Therapeutics 的股票设定了 56.00 美元的目标价。Zacks Research 在 10 月 22 日的研究报告中将 LENZ Therapeutics 的股票评级从 “持有” 上调至 “强力买入”。Weiss Ratings 在 10 月 8 日的报告中重申了 LENZ Therapeutics 的 “卖出（d-）” 评级。Raymond James Financial 在 10 月 20 日的报告中重申了 “跑赢大盘” 评级，并将 LENZ Therapeutics 的目标价上调至 50.00 美元（之前为 40.00 美元）。最后，花旗集团在 7 月 31 日的研究报告中重申了 “买入” 评级，并将 LENZ Therapeutics 的目标价上调至 49.00 美元（之前为 45.00 美元）。一位分析师给予该股票 “强力买入” 评级，五位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，LENZ Therapeutics 目前的平均评级为 “适度买入”，平均目标价为 56.40 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on LENZ Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 LENZ Therapeutics 的最新分析</strong></p>
</div><h2>Hedge Funds Weigh In On LENZ Therapeutics</h2>
<div class="lb-trans"><h2>对 LENZ Therapeutics 的对冲基金看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Versant Venture Management LLC acquired a new stake in shares of LENZ Therapeutics in the third quarter valued at about $123,758,000. Paradigm Biocapital Advisors LP lifted its stake in LENZ Therapeutics by 96.2% in the 1st quarter. Paradigm Biocapital Advisors LP now owns 1,511,932 shares of the company's stock valued at $38,872,000 after buying an additional 741,477 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in LENZ Therapeutics by 108.8% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,122,738 shares of the company's stock worth $32,907,000 after buying an additional 585,000 shares during the last quarter. Saturn V Capital Management LP purchased a new stake in LENZ Therapeutics during the 2nd quarter worth approximately $10,033,000. Finally, Invesco Ltd. acquired a new position in shares of LENZ Therapeutics during the second quarter valued at approximately $7,816,000. 54.32% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近增加或减少了对该股票的持仓。Versant Venture Management LLC 在第三季度收购了价值约 123,758,000 美元的 LENZ Therapeutics 新股份。Paradigm Biocapital Advisors LP 在第一季度将其在 LENZ Therapeutics 的持股增加了 96.2%。Paradigm Biocapital Advisors LP 目前拥有 1,511,932 股公司股票，价值 3,887,200 美元，此前在上个季度又购买了 741,477 股。Adage Capital Partners GP L.L.C.在第二季度将其在 LENZ Therapeutics 的持股增加了 108.8%。Adage Capital Partners GP L.L.C.目前拥有 1,122,738 股公司股票，价值 32,907,000 美元，此前在上个季度又购买了 585,000 股。Saturn V Capital Management LP 在第二季度购买了价值约 10,033,000 美元的 LENZ Therapeutics 新股份。最后，Invesco Ltd.在第二季度收购了价值约 7,816,000 美元的 LENZ Therapeutics 新股份。54.32% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About LENZ Therapeutics</h2>
<div class="lb-trans"><h2>关于 LENZ Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.</p>
<div class="lb-trans"><p>LENZ Therapeutics, Inc.是一家生物制药公司，专注于开发和商业化改善美国视力的疗法。其产品候选包括 LNZ100 和 LNZ101，目前正在进行治疗老花眼的第三阶段临床试验。该公司总部位于加利福尼亚州德尔玛。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than LENZ Therapeutics</li>
<li>Stock Analyst Ratings and Canadian Analyst Ratings</li>
<li>Shares Down, Price Targets Up: 3 Stocks Upgraded After +10% Drops</li>
<li>What is the Euro STOXX 50 Index?</li>
<li>Nuclear Stocks Are Melting Down—Should Investors Panic?</li>
<li>The Role Economic Reports Play in a Successful Investment Strategy</li>
<li>Monday.com Opens Generational Opportunity With Manic Sell-Off</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 LENZ Therapeutics 更好</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>股票下跌，目标价上升：3 只在上涨超过 10% 后被升级的股票</li>
<li>什么是欧元区 STOXX 50 指数？</li>
<li>核能股票正在崩溃——投资者应该恐慌吗？</li>
<li>经济报告在成功投资策略中的作用</li>
<li>Monday.com 因疯狂抛售而开启了世代机会</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in LENZ Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 LENZ Therapeutics 吗？</h2>
</div><p>Before you consider LENZ Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 LENZ Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 LENZ Therapeutics 并不在名单上。</p>
</div><p>While LENZ Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 LENZ Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

James Mccollum 收购了 LENZ Therapeutics (NASDAQ:LENZ) 的 10,500 股股票